Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

State of our campuses: UFS Qwaqwa Campus temporarily closed until 18 April 2017
2017-04-03

The senior leadership of the University of the Free State (UFS) has decided to close the Qwaqwa Campus on Tuesday 28 March 2017 due to student protests regarding provisional registrations. Academic activities will resume on 18 April 2017. 
 
The protests were preceded by a meeting of the campus management with the Student Representative Council (SRC) on 22 March 2017 to discuss issues pertaining to students who are provisionally registered – especially those students who are provisionally registered and awaiting the outcome of their appeals to the National Student Financial Aid Scheme (NSFAS).
 
On 27 March 2017, the SRC handed a memorandum to the campus management, requesting assistance in cases that are on appeal with NSFAS. The students also demanded extension of the provisional registration deadline of 31 March 2017, and that a fundraising plan should be implemented for financially needy students. The campus management made a commitment to respond within the deadline stipulated in the memorandum.
 
After the meeting, violence erupted when a group of students started intimidating students, barricading the entrance to the campus, and damaging university property. An interdict was served by the Sheriff later the same afternoon and additional security was deployed. On 28 March 2017, the violent protests and barricades spilled onto the provincial road to Phuthaditjhaba and several cars were damaged. This led to the arrest of a number of students by members of the South African Police Service for the contravention of the High Court order and for public violence. The students have since been released.
 
Due to the imminent threat to the safety of staff and students on the campus, the senior leadership decided on 28 March 2017 to evacuate the residences and to close the campus temporarily until 18 April 2017.
             
“It is unfortunate that the students resorted to violence without waiting for the campus management’s response to the memorandum of 27 March 2017. What makes the situation difficult is the fact that students on provisional registration who are waiting for the outcome of their NSFAS appeals, are dealing directly with NSFAS. This makes it difficult for the university to intervene,” says Mr Teboho Manchu, acting Principal of the Qwaqwa Campus.
 
The senior leadership of the UFS is aware of the video clip on social media this week, where a student is allegedly beaten by security guards on the Qwaqwa Campus. The senior leadership condemns this deplorable incident. An investigation is underway to determine the nature and cause of the incident. Appropriate steps will be taken once the outcome of the investigation is available.

Released by:
Lacea Loader (Director: Communication and Brand Management)
Telephone: +27 51 401 2584 | +27 83 645 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za
Fax: +27 51 444 6393


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept